Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Mike Westby"'
Autor:
Stephen M. Shaw, Jenny Middleton, Kim Wigglesworth, Amber Charlemagne, Oliver Schulz, Melanie S. Glossop, Giles F. Whalen, Robert Old, Mike Westby, Chris Pickford, Rinat Tabakman, Irit Carmi-Levy, Abi Vainstein, Ella Sorani, Arik A. Zur, Sascha A. Kristian
Publikováno v:
Cancer Cell International, Vol 19, Iss 1, Pp 1-19 (2019)
Abstract Background Treatments that generate T cell-mediated immunity to a patient’s unique neoantigens are the current holy grail of cancer immunotherapy. In particular, treatments that do not require cumbersome and individualized ex vivo processi
Externí odkaz:
https://doaj.org/article/440a5a0ba0874d0aa71454cddd24f71c
Autor:
Marilyn Lewis, Julie Mori, Jonathan Toma, Mike Mosley, Wei Huang, Paul Simpson, Roy Mansfield, Charles Craig, Elna van der Ryst, David L Robertson, Jeannette M Whitcomb, Mike Westby
Publikováno v:
PLoS ONE, Vol 13, Iss 12, p e0204099 (2018)
Detailed clonal phenotypic/genotypic analyses explored viral-escape mechanisms during maraviroc-based therapy in highly treatment-experienced participants from the MOTIVATE trials. To allow real-time assessment of samples while maintaining a blind tr
Externí odkaz:
https://doaj.org/article/e5fed03ceb034b1a93eda448a932be0c
Autor:
D Kireev, Marilyn Lewis, Becky Jubb, E van der Ryst, M Bobkova, Paul Simpson, SL Butler, Charles Craig, Mike Westby, A Lopatukhin
Publikováno v:
Antiviral Chemistry & Chemotherapy, Vol 29 (2021)
Antiviral Chemistry & Chemotherapy
Antiviral Chemistry & Chemotherapy
Introduction Maraviroc inhibits CCR5-tropic HIV-1 across different subtypes in vitro and has demonstrated efficacy in clinical trials. V3-loop amino acid variants observed in individual maraviroc-resistant viruses have not been found to be predictive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e43032e02617aff271537a4c66df3748
https://doaj.org/article/e7be8339c5714171affa6fe5f326b4c2
https://doaj.org/article/e7be8339c5714171affa6fe5f326b4c2
Autor:
Abi Vainstein, Arik A. Zur, Ella Sorani, Giles F. Whalen, Jenny Middleton, Chris Pickford, Melanie S. Glossop, Robert Old, Oliver Schulz, Sascha A. Kristian, Irit Carmi-Levy, Amber Charlemagne, Mike Westby, Rinat Tabakman, Kim Wigglesworth, Stephen M. Shaw
Publikováno v:
Cancer Cell International, Vol 19, Iss 1, Pp 1-19 (2019)
Cancer Cell International
Cancer Cell International
BackgroundTreatments that generate T cell-mediated immunity to a patient’s unique neoantigens are the current holy grail of cancer immunotherapy. In particular, treatments that do not require cumbersome and individualized ex vivo processing or manu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4a18846f7bb9b2696a1417608b07aba
https://doi.org/10.1186/s12935-019-1059-8
https://doi.org/10.1186/s12935-019-1059-8
Autor:
Charles Craig, Marilyn Lewis, Becky Jubb, Elna van der Ryst, Julie Mori, Barry Weatherley, Mike Westby, Phylinda L. S. Chan, Lynn McFadyen, Paul Simpson
Publikováno v:
Antiviral Chemistry & Chemotherapy
Antiviral Chemistry & Chemotherapy, Vol 27 (2019)
Antiviral Chemistry & Chemotherapy, Vol 27 (2019)
Maraviroc blocks HIV-1 entry into CD4+ cells by interrupting the interaction between viral gp120 and cell-surface CCR5. Resistance to CCR5 antagonist–mediated inhibition can develop by unmasking pre-existing CXCR4-using virus or through selection o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4cd1dc80e8f03e572dc94b92865e5ac
http://europepmc.org/articles/PMC6931239
http://europepmc.org/articles/PMC6931239
Autor:
Marilyn Lewis, Mike Westby, Jacqueline K. Flynn, Jingling Zhou, Paula Clarisa Ellenberg, Sharon R Lewin, Melissa J Churchill, Anne Ellett, Kieran Cashin, Katharina Borm, Michael Roche, Becky Jubb, Renee C. Duncan, Lachlan Robert Gray, Jasminka Sterjovski, Paul R Gorry, Benhur Lee
Publikováno v:
AIDS Research and Human Retroviruses. 33:1220-1235
Maraviroc (MVC) is an allosteric inhibitor of human immunodeficiency virus type 1 (HIV-1) entry, and is the only CCR5 antagonist licensed for use as an anti-HIV-1 therapeutic. It acts by altering the conformation of the CCR5 extracellular loops, rend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6d8715dbb68e64b5d3ca84479c4dada
https://doi.org/10.1089/aid.2017.0097
https://doi.org/10.1089/aid.2017.0097
Publikováno v:
Handbook of Biomarkers and Precision Medicine ISBN: 9780429202872
Handbook of Biomarkers and Precision Medicine
Handbook of Biomarkers and Precision Medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdf6c2def49d049baf0b3df48c0929e6
https://doi.org/10.1201/9780429202872-32
https://doi.org/10.1201/9780429202872-32
Autor:
Marilyn Lewis, David Robertson, E van der Ryst, Becky Jubb, John F. Sullivan, Mike Westby, Lynn McFadyen, Paul Simpson, Julie Mori, Charles Craig
Publikováno v:
Antiviral Chemistry & Chemotherapy
Antiviral Chemistry & Chemotherapy, Vol 29 (2021)
Antiviral Chemistry & Chemotherapy, Vol 29 (2021)
Viruses from 15 of 35 maraviroc-treated participants with virologic failure and CCR5-tropic (R5) virus in the MOTIVATE studies at Week 24 had reduced maraviroc susceptibility. On-treatment amino acid changes were observed in the viral envelope glycop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b07dca8da77a9a0ac476e2efe7fda2e2
https://doi.org/10.1177/20402066211030380
https://doi.org/10.1177/20402066211030380
Autor:
Charles Craig, Jonathan Toma, Mike Mosley, Wei Huang, Roy Mansfield, Mike Westby, David Robertson, Paul Simpson, Jeannette M. Whitcomb, Marilyn Lewis, Julie Mori, Elna van der Ryst
Publikováno v:
PLoS ONE, Vol 13, Iss 12, p e0204099 (2018)
PLoS ONE
PLoS ONE
Detailed clonal phenotypic/genotypic analyses explored viral-escape mechanisms during maraviroc-based therapy in highly treatment-experienced participants from the MOTIVATE trials. To allow real-time assessment of samples while maintaining a blind tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a52d4f141be902a83898c2e43b058e7
https://doaj.org/article/e5fed03ceb034b1a93eda448a932be0c
https://doaj.org/article/e5fed03ceb034b1a93eda448a932be0c
Autor:
Marilyn Lewis, Conor J. Meehan, Xiaowei Jiang, Mike Westby, David Robertson, Charles Craig, Grace P. McCormack, Felix Feyertag, Simon A. Travers
Publikováno v:
Journal of Virology
Entry inhibitors represent a potent class of antiretroviral drugs that target a host cell protein, CCR5, an HIV-1 entry coreceptor, and not viral protein. Lack of sensitivity can occur due to preexisting virus that uses the CXCR4 coreceptor, while tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0f3deeffc95215f5f1e9e17a07b3c81
http://europepmc.org/articles/PMC4645647
http://europepmc.org/articles/PMC4645647